| EMA number | EMEA/H/C/002445 |
| ATC code | A10BJ03 |
| Authorisation | 31 January 2013 |
| Withdrawn | 18 December 2025 |
| Revision | 21 |
Lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.
SOLIQUA 100/33 — SANOFI-AVENTIS US, approved 2026-03-12 (BLA208673).
2,658 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.